TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12771523

Group type: EXPERIMENTAL
Intervention: Intravesical treatment with interferon‐a2b (IFN‐a2b); administered weekly for 2 months, then twice a month for 4 months, and monthly for 6 months.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no further treatment); 10 patients.
Number of subjects: 47
Study: 11879269

Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention (six weekly cognitive/behavioral meetings)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (usual psychosocial care)
Number of subjects: 89
Study: 9480241

Group type: EXPERIMENTAL
Intervention: Examined group (pH < 7.30)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (pH = 7.30)
Number of subjects: 64
Study: 7930245

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty of the left anterior descending coronary artery (Group IA, n = 9)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty of a major artery (Group IB, n = 11)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Coronary angiography without coronary angioplasty (Group II, n = 12)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Right heart catheterization without angiography (Group III, n = 13)
Number of subjects: 45
Study: 3079010

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg three times daily
Number of subjects: 114
Study: 1944608

Group type: EXPERIMENTAL
Intervention: 1, 3, or 5 x 10(6) units of recombinant alpha‐interferon
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 x 10(6) units of recombinant alpha‐interferon
Number of subjects: 10
Study: 339448

Group type: EXPERIMENTAL
Intervention: Twice-weekly continuation regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Twice-weekly continuation regimen of streptomycin plus isoniazid after 6 weeks of initial daily triple chemotherapy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Once-weekly regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: 12 months of chemotherapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: 18 months of chemotherapy
Number of subjects: 272
Study: 31751908

Group type: EXPERIMENTAL
Intervention: Long sleep opportunity (time in bed: 9.5 h/night)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Short sleep opportunity (time in bed: 6.5 h/night)
Number of subjects: 54
Study: 31046752

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention promoting clinical algorithms for caesarean decision-making (in-site training, audits, feedback, SMS reminders)
Number of subjects: 4174

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4174

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 4174
Study: 29052529

Group type: EXPERIMENTAL
Intervention: Enhanced ART-adherence support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 26097987

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24167993

Group type: EXPERIMENTAL
Intervention: Transoral endoscopic adenoidectomy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no adenoidectomy)
Number of subjects: 83
Study: 20640848

Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG) applied after prosthesis implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no APG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: APG group
Number of subjects: 40
Study: 19813467

Group type: EXPERIMENTAL
Intervention: Test formulation of clarithromycin suspension (500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of clarithromycin suspension (500 mg)
Number of subjects: 24
Study: 17541852

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in females with poor metabolic status (PM)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in males with poor metabolic status (PM)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in females with extensive metabolic status (EM)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment in males with extensive metabolic status (EM)
Number of subjects: 55
Study: 12786918

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (9 mg/kg per day by mouth divided 3 times a day with food)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 10925968

Group type: EXPERIMENTAL
Intervention: Celecoxib 25-400 mg b.i.d.
Number of subjects: 11008

Group type: COMPARATOR
Intervention: Nonspecific NSAIDs (naproxen 500 mg b.i.d., diclofenac 50 or 75 mg b.i.d., ibuprofen 800 mg t.i.d.)
Number of subjects: 11008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11008

Group type: EXPERIMENTAL
Intervention: Celecoxib 100-400 mg b.i.d. (long-term open-label trial)
Number of subjects: 11008
Study: 8642439

Group type: EXPERIMENTAL
Intervention: Marine oil eicosapentaenoic acid (EPA) (0.3%) and docosahexaenoic acid (DHA) (0.2%) added to formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marine oil DHA (0.2%) with less EPA (0.06%) fed for a shorter interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AA (0.43%) and DHA (0.1%)
Number of subjects: 0
Study: 1346505

Group type: EXPERIMENTAL
Intervention: Zidovudine 400 mg daily
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Zidovudine 800 mg daily
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Zidovudine 1200 mg daily
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Zidovudine (all doses)
Number of subjects: 474
Study: 6593147

Group type: EXPERIMENTAL
Intervention: Amine fluoride gel (5 min once weekly)
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Fluoride-free dentifrice (twice daily)
Number of subjects: 1286
Study: 31570028

Group type: EXPERIMENTAL
Intervention: Dilapan-S with 200 mg oral mifepristone (study group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Dilapan-S alone (control group)
Number of subjects: 127
Study: 30728457

Group type: EXPERIMENTAL
Intervention: Azacitidine (given prior to therapy with idarubicin and etoposide)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Azacitidine (given concurrently with idarubicin and etoposide)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Azacitidine (given after therapy with idarubicin and etoposide)
Number of subjects: 268

Group type: COMPARATOR
Intervention: STANDARD (idarubicin, cytarabine, etoposide)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Azacitidine-containing arms
Number of subjects: 268
Study: 28407823

Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal cannula (HHFNC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 78
Study: 25313094

Group type: EXPERIMENTAL
Intervention: Inosine 3 g/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23964657

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 24
Study: 22281895

Group type: EXPERIMENTAL
Intervention: Pentamidine isethionate
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Number of subjects: 185

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 185
Study: 19012060

Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer (VM)
Number of subjects: 40
Study: 17110281

Group type: EXPERIMENTAL
Intervention: TCH346 0.5 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: TCH346 2.5 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: TCH346 10 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: TCH346 (all doses)
Number of subjects: 301
Study: 15538621

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 7446

Group type: COMPARATOR
Intervention: Open hernioplasty
Number of subjects: 7446

Group type: EXPERIMENTAL
Intervention: Endoscopic hernia repair
Number of subjects: 7446
Study: 10981568

Group type: EXPERIMENTAL
Intervention: Tenoxicam i.p. group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tenoxicam i.v. group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 90
Study: 9237082

Group type: EXPERIMENTAL
Intervention: 19 hr of food deprivation and a stressor (difficult to solve anagrams)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Negative affect (anxiety, depression, and anger)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Food deprivation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 56
Study: 8414858

Group type: EXPERIMENTAL
Intervention: Warm room (mean ambient temperature 25.7 degrees C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cool room (mean temperature 19.4 degrees C)
Number of subjects: 32
Study: 2871667

Group type: EXPERIMENTAL
Intervention: Celiprolol (100 mg oral dose, given 6 hours after symptom onset)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Celiprolol and Placebo
Number of subjects: 21
Study: 31644731

Group type: EXPERIMENTAL
Intervention: Music therapy for caregivers
Number of subjects: 69
Study: 28520735

Group type: EXPERIMENTAL
Intervention: Methadone initiation
Number of subjects: 168
Study: 26188189

Group type: EXPERIMENTAL
Intervention: GEC-TGF-β1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 23739574

Group type: EXPERIMENTAL
Intervention: DEX (0.5‐1.0 μg/kg load, 0.2‐0.6 μg×kg⁻¹×h⁻¹ for 24 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol (0.5‐2.0 mg/kg load, 1‐3 mg×kg⁻¹×h⁻¹ for 72 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pethidine and other temporary medication (group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (Propofol)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group A (DEX)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (Pethidine)
Number of subjects: 90
Study: 22051828

Group type: EXPERIMENTAL
Intervention: Linfonex™ 1000 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cellcept™ 1000 mg
Number of subjects: 22
Study: 19292423

Group type: EXPERIMENTAL
Intervention: Knee arthroscopic partial meniscectomy
Number of subjects: 83
Study: 16874422

Group type: EXPERIMENTAL
Intervention: Nickel sulphate patch test
Number of subjects: 93

Group type: COMPARATOR
Intervention: Negative fragrance patch test
Number of subjects: 93
Study: 11469295

Group type: EXPERIMENTAL
Intervention: KT‐308 alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: KT‐308 with a single gutta‐percha cone (SCGP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ZUT alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ZUT with SCGP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH26 alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH26 with SCGP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Positive control - no root canal filling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Negative control - no root canal filling, sealed with C&B Metabond cement
Number of subjects: 80
Study: 9207576

Group type: EXPERIMENTAL
Intervention: Superovulation with FSH and IUI
Number of subjects: 311

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 311
Study: 8094349

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg every 8 h for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (same regimen as Nifedipine)
Number of subjects: 30
Study: 3322097

Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg.kg‐1, 0.25 mg.kg‐1, 0.30 mg.kg‐1, 0.35 mg.kg‐1, 0.40 mg.kg‐1 (open study)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Midazolam 0.2 mg.kg‐1 (double-blind study)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (double-blind study)
Number of subjects: 102
Study: 29775954

Group type: EXPERIMENTAL
Intervention: Target group with specific physical therapy techniques added to conventional protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with conventional physical therapy protocol
Number of subjects: 30
Study: 28418172

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Active placebo tolterodine 1 mg
Number of subjects: 49
Study: 25661312

Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB) using lidocaine with epinephrine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (further intravenous morphine only)
Number of subjects: 24
Study: 23301896

Group type: EXPERIMENTAL
Intervention: 250 mg ginseng twice daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21129375

Group type: EXPERIMENTAL
Intervention: Peginterferon (half-dose)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with cirrhosis)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Control (for patients with cirrhosis)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with fibrosis)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Control (for patients with fibrosis)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with a ≥ 2-point decrease in histologic activity index)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with unchanged or increased histologic activity index)
Number of subjects: 1048
Study: 18351194

Group type: EXPERIMENTAL
Intervention: Patient-directed intervention (e-mails and nurse telephone calls)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Reminder-only (computerized reminders)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Patient-directed intervention (in subgroup with no aspirin use at baseline)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Reminder-only (in subgroup with no aspirin use at baseline)
Number of subjects: 334
Study: 16554198

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 31

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 31
Study: 14600858

Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg/kg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Retrobulbar anaesthesia (Mepivacain 2 %/Bupivacain 0.5 %)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dolasetron 12.5 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline (0.9 %)
Number of subjects: 102
Study: 10913923

Group type: EXPERIMENTAL
Intervention: Serum CTX measured in the early afternoon (1-2 PM)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Urinary CTX
Number of subjects: 854

Group type: COMPARATOR
Intervention: Free deoxypyridinoline
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Serum CTX from morning samples
Number of subjects: 854
Study: 7778963

Group type: EXPERIMENTAL
Intervention: Outpatient GEM team clinic
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study: 2224663

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 104

Group type: COMPARATOR
Intervention: Tobramycin plus clindamycin or metronidazole (Control)
Number of subjects: 104
Study: 39585

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol and 100 mg metoprolol
Number of subjects: 9
Study: 31051322

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy – Adolescent Skills Training (IPT‐AST)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Group Counseling (GC)
Number of subjects: 167
Study: 28904084

Group type: EXPERIMENTAL
Intervention: SV runs group
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: pAF detected after cerebral ischemia
Number of subjects: 254

Group type: COMPARATOR
Intervention: Controls (no SV runs)
Number of subjects: 254
Study: 25959196

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24579278

Group type: EXPERIMENTAL
Intervention: Chemo mechanical (carie care) caries removal method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Airotor hand instruments
Number of subjects: 20
Study: 20842070

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18316395

Group type: EXPERIMENTAL
Intervention: Moderate daily alcohol consumption (16.4‐42.6 g ethanol/day)
Number of subjects: 8576

Group type: COMPARATOR
Intervention: Nondrinkers with the highest GGT
Number of subjects: 8576

Group type: EXPERIMENTAL
Intervention: Moderate or heavy alcohol drinkers (>or=42.7 g ethanol/day)
Number of subjects: 8576

Group type: EXPERIMENTAL
Intervention: GGT and ALT levels
Number of subjects: 8576

Group type: COMPARATOR
Intervention: Nondrinkers with the highest GGT or ALT
Number of subjects: 8576
Study: 16602254

Group type: EXPERIMENTAL
Intervention: HBO2 treatment at 2.4 atm abs pressure with 90 minutes of 100% oxygen breathing
Number of subjects: 30

Group type: COMPARATOR
Intervention: US Air Force CO protocol (3.0 atm abs maximum pressure)
Number of subjects: 30
Study: 12963554

Group type: EXPERIMENTAL
Intervention: Gastric acid-lowering medications (histamine receptor H2 antagonists or proton pump inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving gastric acid-lowering medications)
Number of subjects: 0
Study: 9049782

Group type: EXPERIMENTAL
Intervention: Intraglobin-F
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sandoglobulin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gamimune-N, Sandoglobulin, Gammagard
Number of subjects: 27
Study: 8290213

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate hydrochloride for 1 week postoperatively
Number of subjects: 160

Group type: COMPARATOR
Intervention: Noncycloplegic group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall postoperative flare
Number of subjects: 160
Study: 3494005

Group type: EXPERIMENTAL
Intervention: Pelvic irradiation followed by a prostate boost
Number of subjects: 526

Group type: COMPARATOR
Intervention: Pelvic and periaortic irradiation followed by a prostate boost
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Doses to the prostate in excess of 7000 cGy
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Pelvic irradiation techniques
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Lateral boost technique and perineal boost technique
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Total dose to the regional lymphatics (4400 to 5100 cGy)
Number of subjects: 526
Study: 29797500

Group type: EXPERIMENTAL
Intervention: real‐rTMS (for five consecutive days in 20‐min sessions)
Number of subjects: 15

Group type: COMPARATOR
Intervention: sham‐rTMS (for five consecutive days in 20‐min sessions)
Number of subjects: 15
Study: 26695388

Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation (IRV) with I:E ratio of 2:1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional ventilation with I:E ratio of 1:2
Number of subjects: 60
Study: 24621025

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison of VAS scores and patient satisfaction
Number of subjects: 17
Study: 22499965

Group type: EXPERIMENTAL
Intervention: Oral Impact for 5 days before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional diet before surgery
Number of subjects: 30
Study: 20045497

Group type: EXPERIMENTAL
Intervention: Statin (simvastatin, moderate to high dose)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 212
Study: 17901413

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter for 12 months
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 15486003

Group type: EXPERIMENTAL
Intervention: Atropine, 20 microg kg(‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil, 1 microg kg(‐1) injected over 60 s, followed by infusion of 0.25 microg kg(‐1) min(‐1) for 10 min then 0.5 microg kg(‐1) min(‐1) for 10 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ringer's lactate (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40
Study: 12202963

Group type: EXPERIMENTAL
Intervention: High-dose clonidine (2.5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10489843

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (100 microg or 200 microg daily)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 8998488

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Euroqol
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: OPCS Disability Survey
Number of subjects: 380
Study: 1728438

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (600 mg p.o.)
Number of subjects: 20
Study: 6731326

Group type: COMPARATOR
Intervention: Metoprolol (beta 1-selective blocker), administered intravenously followed by oral treatment for 3 months.
Number of subjects: 1395